Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight ...

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned an average rating of “Buy” from the ...

This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a ...

Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention ... This work provides a systematic study of the solubility, structure, oligomerization, and long-term stability ...

Glucagon-like peptide-1 (GLP-1) medications are doing more than transforming ... how these drugs are administered and potentially affect their accessibility and cost structure. The adoption of GLP-1 ...

Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling ...

Speaking to Francesca Rudkin and Louise Ayrey on their NZ Herald podcast, The Little Things, he said many of these medications belong to a group of drugs called glucagon-like peptide-1 (GLP-1 ...

Losing weight on a GLP-1 medication can have emotional and physical effects. Some changes are easier to handle than others, but users say the benefits are worth the effort.

AAV is a virus with low immunogenicity and a simple structure, used for delivering ... as various bioactive substances, with glucagon-like peptide (GLP)-1 being a representative example.